Akamis Bio (Group)

https://www.akamisbio.com

LinkedIn: https://www.linkedin.com/company/psioxus

Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis Bio has a growing pipeline of T-SIGn® therapeutics anchored by its two clinical-stage programs, NG-350A (an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody) and NG-641 (a stromal-targeted tumor gene therapy leveraging a viral vector encoding a FAP-CD3 bispecific antibody, CXCL-9, CXCL-10 & interferon alpha). NG-350A and NG-641 are both being investigated in ongoing Phase 1 clinical studies in patients with metastatic or advanced epithelial tumors. In addition to internal pipeline development efforts, Akamis Bio has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI). *

	Start	2023-01-05 renamed
	Predecessor	PsiOxus Therapeutics Ltd.
	Industry	oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy)
	Person	Davis, Howard E. (PsiOxus 202208– CEO based in Boston area before Atlas Venture + Third Harmonic Bio + Flagship)
	Person 2	Paoletti, Paolo (GammaDelta Therapeutics 201705– CEO before Kesios Therapeutics CEO + GSK)

	Region	Abingdon, Oxfordshire
	Country	United Kingdom (GB)
	Street	Barton Lane Abingdon Science Park, The Quadrant, 4-10
	City	OX14 3YS Abingdon, Oxfordshire
	Tel	+44-1235-835328
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Akamis Bio Ltd.. (1/5/23). "Press Release: Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics". Cambridge, MA & Oxford.

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Akamis Bio (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)